Final answer:
Increased extracellular volume in conditions like cirrhosis or CHF can affect the dosing of non-depolarizing neuromuscular blockers.
Step-by-step explanation:
Increased extracellular volume, such as in cirrhosis or congestive heart failure (CHF), can have an effect on the dosing of non-depolarizing neuromuscular blockers. The increased volume results in dilution of the drug in the extracellular fluid, leading to a decreased concentration at the binding sites on the neuromuscular receptors. As a result, higher doses of the neuromuscular blocker may be needed to achieve the desired effect.